AU2019404552A1 - Amorphous sparsentan compositions - Google Patents
Amorphous sparsentan compositions Download PDFInfo
- Publication number
- AU2019404552A1 AU2019404552A1 AU2019404552A AU2019404552A AU2019404552A1 AU 2019404552 A1 AU2019404552 A1 AU 2019404552A1 AU 2019404552 A AU2019404552 A AU 2019404552A AU 2019404552 A AU2019404552 A AU 2019404552A AU 2019404552 A1 AU2019404552 A1 AU 2019404552A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- pharmaceutical composition
- amorphous
- pharmaceutically acceptable
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783947P | 2018-12-21 | 2018-12-21 | |
| US62/783,947 | 2018-12-21 | ||
| PCT/US2019/068094 WO2020132594A1 (en) | 2018-12-21 | 2019-12-20 | Amorphous sparsentan compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019404552A1 true AU2019404552A1 (en) | 2021-07-15 |
Family
ID=69187971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019404552A Abandoned AU2019404552A1 (en) | 2018-12-21 | 2019-12-20 | Amorphous sparsentan compositions |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220048900A1 (https=) |
| EP (1) | EP3897834A1 (https=) |
| JP (1) | JP2022514569A (https=) |
| KR (1) | KR20210125994A (https=) |
| CN (1) | CN114126712A (https=) |
| AU (1) | AU2019404552A1 (https=) |
| BR (1) | BR112021012226A2 (https=) |
| CA (1) | CA3124127A1 (https=) |
| IL (1) | IL284186A (https=) |
| MA (1) | MA54542A (https=) |
| MX (1) | MX2021007258A (https=) |
| WO (1) | WO2020132594A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53817A (fr) | 2018-10-04 | 2021-08-11 | Travere Therapeutics Inc | Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv |
| WO2022266370A1 (en) | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| EP4458826A4 (en) * | 2021-12-28 | 2025-12-24 | Alchemedicine Inc | COMPOUND, ANGIOTENSIN II TYPE 1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION |
| JP2025183466A (ja) * | 2022-11-11 | 2025-12-17 | 株式会社アークメディスン | 化合物、エンドセリンa受容体拮抗剤、アンジオテンシンiiタイプ1受容体拮抗剤及び医薬組成物 |
| KR20250151548A (ko) * | 2023-02-24 | 2025-10-21 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 방향족 고리계 함유 유도체 길항제의 염, 이의 제조 방법과 응용 |
| CN118666826A (zh) * | 2024-08-23 | 2024-09-20 | 成都臻拓医药科技有限公司 | 一种司帕生坦原料药的重结晶纯化方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| ATE339417T1 (de) * | 1999-12-15 | 2006-10-15 | Bristol Myers Squibb Co | Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten |
| WO2010114801A1 (en) * | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| WO2010135350A2 (en) * | 2009-05-20 | 2010-11-25 | Pharmacopeia, Llc | Biphenyl intermediate compounds and methods for the preparation of a dual angiotensin ii and endothelin a receptor antagonist |
| CN117017985A (zh) * | 2016-10-13 | 2023-11-10 | 特拉维尔治疗公司 | 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 |
-
2019
- 2019-12-20 US US17/415,518 patent/US20220048900A1/en not_active Abandoned
- 2019-12-20 AU AU2019404552A patent/AU2019404552A1/en not_active Abandoned
- 2019-12-20 MX MX2021007258A patent/MX2021007258A/es unknown
- 2019-12-20 MA MA054542A patent/MA54542A/fr unknown
- 2019-12-20 WO PCT/US2019/068094 patent/WO2020132594A1/en not_active Ceased
- 2019-12-20 CA CA3124127A patent/CA3124127A1/en active Pending
- 2019-12-20 JP JP2021535041A patent/JP2022514569A/ja active Pending
- 2019-12-20 CN CN201980092448.1A patent/CN114126712A/zh active Pending
- 2019-12-20 BR BR112021012226-5A patent/BR112021012226A2/pt not_active IP Right Cessation
- 2019-12-20 EP EP19842514.2A patent/EP3897834A1/en not_active Withdrawn
- 2019-12-20 KR KR1020217021973A patent/KR20210125994A/ko not_active Ceased
-
2021
- 2021-06-20 IL IL284186A patent/IL284186A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3124127A1 (en) | 2020-06-25 |
| MX2021007258A (es) | 2021-08-16 |
| US20220048900A1 (en) | 2022-02-17 |
| EP3897834A1 (en) | 2021-10-27 |
| BR112021012226A2 (pt) | 2021-09-08 |
| KR20210125994A (ko) | 2021-10-19 |
| IL284186A (en) | 2021-08-31 |
| WO2020132594A1 (en) | 2020-06-25 |
| JP2022514569A (ja) | 2022-02-14 |
| CN114126712A (zh) | 2022-03-01 |
| MA54542A (fr) | 2021-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220048900A1 (en) | Amorphous sparsentan compositions | |
| US20250325522A1 (en) | Biphenyl sulfonamide compounds for the treatment of kidney diseases or disorders | |
| JP7409696B2 (ja) | キナーゼ阻害剤の塩およびその組成物 | |
| US20090191265A1 (en) | Capsule Formulation of Pirfenidone and Pharmaceutically Acceptable Excipients | |
| WO2022246200A1 (en) | Methods of treating kidney diseases or disorders | |
| JP2001511450A (ja) | チアガビンを含有する制御放出性の医薬組成物 | |
| KR102301743B1 (ko) | 에피나코나졸 경구용 조성물 | |
| US20100008956A1 (en) | Composition and combinations of carboxylic acid losartan in dosage forms | |
| WO2024073672A1 (en) | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders | |
| AU2024343419A1 (en) | Sparsentan for treating immunoglobulin a nephropathy (igan) | |
| US20210052608A1 (en) | Methods of treating bacterial infections with minocycline | |
| WO2022264004A1 (en) | Pharmaceutical composition comprising itraconazole | |
| US20220175774A1 (en) | Bioavailable Oral Dosage Form Of Tyrosine-Kinase Inhibitor | |
| BR122025008185A2 (pt) | Usos terapêuticos de compostos de bifenil sulfonamida para a fabricação de um medicamento para tratar doenças ou transtornos renais em um indivíduo | |
| HK1168758A (en) | Capsule formulation of pirfenidone and pharmaceutically acceptable excipients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |